{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:49:21Z","timestamp":1779306561307,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,4,6]],"date-time":"2014-04-06T00:00:00Z","timestamp":1396742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00415-014-7336-5","type":"journal-article","created":{"date-parts":[[2014,4,5]],"date-time":"2014-04-05T09:37:59Z","timestamp":1396690679000},"page":"1139-1143","source":"Crossref","is-referenced-by-count":30,"title":["Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?"],"prefix":"10.1007","volume":"261","author":[{"given":"Mike P.","family":"Wattjes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Vennegoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jop","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bob W.","family":"van Oosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,6]]},"reference":[{"key":"7336_CR1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamaneurol.2013.598","volume":"70","author":"R Rudick","year":"2013","unstructured":"Rudick R, Polman C, Clifford D, Miller D et al (2013) Natalizumab: bench to bedside and beyond. JAMA Neurol 70:172\u2013182","journal-title":"JAMA Neurol"},{"key":"7336_CR2","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB et al (2013) PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology 80:1430\u20131438","journal-title":"Neurology"},{"key":"7336_CR3","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2012-302478","volume":"83","author":"D Mentzer","year":"2012","unstructured":"Mentzer D, Prestel J, Adams O et al (2012) Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry 83:927\u2013933","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7336_CR4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ana.23676","volume":"72","author":"TA Yousry","year":"2012","unstructured":"Yousry TA, Pelletier D, Cadavid D et al (2012) MRI pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 72:779\u2013787","journal-title":"Ann Neurol"},{"key":"7336_CR5","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1177\/1352458513510224","volume":"19","author":"MP Wattjes","year":"2013","unstructured":"Wattjes MP, Richert ND, Killestein J et al (2013) The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 19:1826\u20131840","journal-title":"Mult Scler"},{"key":"7336_CR6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/WNL.0b013e318246d6d8","volume":"78","author":"NF Blair","year":"2012","unstructured":"Blair NF, Brew BJ, Halpern JP (2012) Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance. Neurology 78:507\u2013508","journal-title":"Neurology"},{"key":"7336_CR7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00415-013-7191-9","volume":"261","author":"J Havla","year":"2014","unstructured":"Havla J, Hohlfeld R, K\u00fcmpfel T (2014) Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstem. J Neurol 261:232\u2013234","journal-title":"J Neurol"},{"key":"7336_CR8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jnnp-2011-300511","volume":"83","author":"R Phan-Ba","year":"2012","unstructured":"Phan-Ba R, Lommers E, Tshibanda L et al (2012) MRI preclinical detection and asymptomatic course of a progressive multifocal leukoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 83:224\u2013226","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7336_CR9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fneur.2013.00011","volume":"4","author":"H Lind\u00e5","year":"2013","unstructured":"Lind\u00e5 H, von Heijne A (2013) Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy. Front Neurol 4:11","journal-title":"Front Neurol"},{"key":"7336_CR10","unstructured":"Dong-Si T, Richman S, Bloomgren G et al (2013) Survival and functional outcome in asymptomatic natalizumab-associated progressive multifocal leukoencephalopathy multiple sclerosis patients. Mult Scler 19: (S1) P879 Presented at ECTRIMS Copenhagen, 2013"},{"key":"7336_CR11","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ana.22137","volume":"68","author":"CF Ryschkewitsch","year":"2010","unstructured":"Ryschkewitsch CF, Jensen PN, Monaco MC, Major EO (2010) JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol 68:384\u2013391","journal-title":"Ann Neurol"},{"key":"7336_CR12","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1212\/WNL.0b013e31823b9b27","volume":"77","author":"J Kuhle","year":"2011","unstructured":"Kuhle J, Gosert R, B\u00fchler R et al (2011) Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 77:2010\u20132016","journal-title":"Neurology"},{"key":"7336_CR13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ana.24051","volume":"75","author":"AJ Fine","year":"2014","unstructured":"Fine AJ, Sorbello A, Kortepeter C, Scarazzini L (2014) Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann Neurol 75:108\u2013115","journal-title":"Ann Neurol"},{"key":"7336_CR14","doi-asserted-by":"crossref","unstructured":"Wattjes MP, Killestein J (2014) PML after natalizumab discontinuation: few and true? Ann Neurol 75:462","DOI":"10.1002\/ana.24110"},{"key":"7336_CR15","unstructured":"Warnke C, Markwerth P, Pawlita M et al (2013) The anti-JC virus antibody index in CSF for diagnosis of progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis. Mult Scler (S1): 181. Presented at ECTRIMS Copenhagen, 2013"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-014-7336-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-014-7336-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-014-7336-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:22:38Z","timestamp":1559071358000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-014-7336-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["7336"],"URL":"https:\/\/doi.org\/10.1007\/s00415-014-7336-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,6]]}}}